NCT03907475 2026-03-18
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute
AstraZeneca
Institut Bergonié
GI Innovation, Inc.
The Netherlands Cancer Institute